Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd., founded in 1996, is an innovative biopharmaceutical company in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for unmet medical needs, such as viral hepatitis and malignant tumors, and immunotherapy. Looking into the future, Amoytop Biotech is especially focusing on CHB (chronic hepatitis B) treatment and will keep advancing the clinical research progress of multiple ongoing pipeline programs aiming to achieve breakthroughs in the clinical cure of CHB.